Risuteganib

DB14911InvestigationalSmall molecule

Risuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema).

Formula / weight: C₂₂H₃₉N₉O₁₁S · 637.67 g/mol (avg)
Code names: ALG-1001

Resolves to

Compound

UNII123DNA66IACAS1307293-62-4

Structure

InChIKeyMYZAXBZLEILEBR-RVFOSREFSA-NSMILESC[C@@H](O)[C@H](NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O

Targets

O43915VEGFDP49767VEGFCP49765VEGFBP15692VEGFA

What you can answer from here — as of April 23, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Risuteganib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account